STEM CELLS IN ACUTE MYELOID LEUKEMIAS
Keywords:
acute myeloid leukemias, leukemic stem cell, microRNAs.Abstract
Summary. The existence of leukemic stem cells (LSC) in acute myeloid leukemias was firstly evidenced in 1997. LSC arise from haematopoietic stem cells or commited he-matopoietic progenitor cells. During the process of malignant transformation they acquire the capacity of self-renewal, proliferation and differention through gene tic and epigene-tic alteration and clonal diversification. The surface mark-ers of LSC are heterogenous. In regulation of LSC play im-portant role the interaction with their microenvironment, critical signaling pathways and non-coding RNAs. Further efforts are needed to develop efficient LSC-based treatment of leukemia
References
Fialkow P. Acute nonlymphoblastic leukemia: heterogene-ity of stem cell origin. Blood 1981; 57: 1068–73.2. Dick JE. Normal and leukemic stem cells assayed in SCID mice. Semin Immunol 1996; 8: 197–206.3. Passegue E, Jamleson CHM, Ailles LE, Weissman IL. Nor-mal and leukemic hematopoiesis: are leukemias a stem cell disor-ders or a reaquisition of stem cell characteristics. Proc Natl Acad Sci USA 2003; 100: 11842–49.4. Huntly BJD, Gilliland DG. Leukemia stem cells and the evolution of cancer stem cell research. Nat Rev Cancer 2005; 5: 311–20.5. Reya T, Morrison S, Clarke M, Weissman I. Stem cells, can-cer and cancer stem cells. Nature 2011; 414: 105–11.6. Bonnet D, Dick JE. Human acute myeloid leukemia is or-ganised as a hierarchy that originate from primitive hematopoiet-ic cell. Nat Med 1997; 3 (7): 730–37.7. Wang JCY, Dick JE. Cancer stem cells. In: Devita, Hell-man and Rosenberg’s Cancer: Principles and Practice of Oncol-ogy, 8th ed. N.Y.: Lippincot Williams and Wilkins, 2008: 136–46.8. Surry JE, Murphy K, Perry R, et al.Human acute myeloge-nous leukemia stem cells are rare and heterogenous when assayed in NOD/SCID/IL2Rγc-deficient mice. J Clin Invest 2011; 121(1): 384–95.9. Thomas D, Majeti R. Biology and relevance of human acute myeloid leukemia stem cells. Blood 2017; 129 (12): 1577–85.10. Dick JE. Acute myeloid leukaemia stem cells. Ann NY Acad Sci 2005; 1044: 1–5.11. Pabst C, Bergeron A, Lavallec VP, et al.GPR56 identifies primary human acute myeloid leukemia cells was high repopulat-ing potential in vivo. Blood 2016; 127 (16): 2018–27.12. Iwasaki M, Liedtke M, Gentles AJ, Cleary ML. CD93 marks a non-quiescent human leukemia stem cell population and is re-quired for development of MLL-rearrangement acute myeloid leu-kemia. Cell Stem Cells 2015; 17 (4): 412–21.13. Eppert K, Takenaka K, Lechman ER, et al.Stem cell gene expression programs influence clinical outcome in human leuke-mia. Nat Med 2011; 17 (9): 1086–93.14. Taussig DC, Vargaftig J, Miraki-Moud F, et al.Leukemia-initiating cells from some acute myeloid leukemia patients with mu-tated nucleophosmin reside in the CD34(–)fraction. Blood 2010; 115 (10): 1976–84.15. Quek L, Otto GM, Garnett C, et al.Genetically distinct leukemic stem cells in human CD34– acute myeloid leukemia are arrested at a hematopoietic precursor-like stage. J Exp Med 2016; 213 (8): 1513–35.16. Miyamoto T, Weissman IL, Akashi K. AML1/ETO expres-sion nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci USA 2000; 97 (13): 7521–26.17. Guibal FC, Alterich-Jorda M, Hirai H, et al.Identification of a myeloid comitted progenitor as the cancer-initiating in acute promyelocytic leukemia. Blood 2009; 114 (27): 5415–25.18. Чертков ИЛ, Гуревич ОА. Стволовая кроветворная клетка и ее микроокружение. М: Медицина, 1984. 240 с.19. Colmone A, Amorim M, Pontier AL, et al.Leukemic cells create bone marrow niches that disrupt the behavior of normal he-matopoietic progenitor cells. Science 2008; 322: 1861–65.20. Konopleva MY, Jordan CT. Leukemia stem cells and mi-croenvironment: biology and therapeutic targeting. J Clin Oncol 2011; 29: 591–99.21. Spoo AC, Lubbert M, Wierda WC, Burger JA.CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 2007; 109: 786–91.22. Jacamo R, Chen Y, Wang Z, et al.Reciprocal leukemia-stro-ma VCAM-1/VLA-4 dependent activation of NF-kappaB medi-ates chemoresistance. Blood 2014; 123: 2691–702.23. Mardis ER, Ding L, Dooling DJ, et al.Recurring muta-tions found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058–66.24. Greif PA, Eck SH, Konstandin NP, et al.Identification of recurring tumor-specific somatic mutations in acute my-eloid leukemia by transcriptome sequencing. Leukemia 2011; 25: 821–27.25. Cancer Genome Atlas Research. Genomic and epigenom-ic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059–74.26. Kreso A, Dick JE. Evolution of the cancer stem cell mod-el. Cell Stem Cell 2014; 14 (3): 275–91.27. Wang K, Sanchez-Martin M, Wang X, et al.Patient-de-rived xenotransplantants can recapitulate the genetic driven land-scape of acute leukemia. Leukemia 2017; 31 (1): 151–58.28. Wang X, Huang Sh, Chen J-L. Understanding of leuke-mic stem cells and their clinical implications. Mol Cancer 2017; 16 (2): 1–27.29. Saito Y, Uchida N, Tanaka S, et al.Induction of cell cy-cle entry eliminates human leukemia stem cells in mouse model of AML. Nat Biotechnol 2010; 28 (3): 275–80.30. Jin L, Lee EM, Ramshaw HS, et al.Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, elimi-nates human acute myeloid leukemia stem cells. Cell Stem Cell 2009; 5 (1): 31–42.31. Schepers K, Pietras EM, Reynaud D, et al.Myelopro-liferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemia niche. Cell Stem Cell 2013; 13: 285–89.32. Wang Y, Krivtsov AV, Sinha AU, et al.The Want/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010; 327: 1650–53.33. Siapati EK, Papadaki M, Kozaou Z, et al.Proliferation and bone marrow engraftment of AML blasts is dependent on beta-catenin signalling. Br J Haematol 2011; 152: 164–74.
Zhao C, Chen A, Jamieson CH, et al.Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leuke-mia. Nature 2009; 458: 776–79.35. Reya T, Duncan AW, Ailles L, et al.A role for Wnt signal-ling in self-renewal of haematopoietic stem cells. Nature 2003; 423: 404–14.36. Cobas M, Wilson A, Ernst B, et al.Beta-catenin in dis-pensable for hematopoiesis and lymphopoiesis. J Exp Med 2004; 199: 211–13.37. Duchartre Y, Kim YM, Kahn M. The Wnt signalling path-way in cancer. Crit Rev Oncol Hematol 2016; 99: 141–49.38. Griffiths EA, Gore SD, Hooker C, et al.Acute myeloid leu-kemia is characterized by Wnt pathway inhibitor promotor hyper-methylation. Leuk Lymphoma 2010; 51: 1711–19.39. Guzman ML, Rossi RM, Karnischky L, et al.The sesqui-terpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005; 105: 4163–69.40. Costello RT, Mallet F, Gaugler B, et al.Human acute my-eloid leukemia CD34+/CD38– progenitor cells have decreased sen-sitivity to chemotherapy and FAS-induced apoptosis, reduced im-munogenicity, and impaired dendritic cell transformation capac-ities. Cancer Res 2000; 60: 4403–11.41. Аушев ВН. МикроРНК: малые молекулы с большим значением. Онкогематология 2015; 8 (1): 1–12.42. Liao Q, Wang B, Li X, Jiang G. miRNAs in acute myeloid leukemia. Oncotarget 2017; 8 (2): 3666–82.43. Weiss CN, Ito K. A macro view of microRNAs: the disco-very of microRNAs and their role in hematopoiesis and hemato-logic disease. Int Rew Cell Mol Biol 2017; 334: 99–175.44. Bousquet M, Quelen C, Rosati R, et al.Myeloid cell differ-entiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid keukemia with the t(11;14)(p21;q23) translocation. J Exp Med 2008; 205 (11): 2499–506.45. Lechman ER, Gentner B, Ng SWK, et al.MiR-126 regu-lates distinct self-renewal outcomes in normal and malignant he-matopoietic stem cells. Cancer Cell 2016; 29 (4): 214–28.46. Dorrance AM, Neviant P, Ferenchak GJ, et al.Targeting leukemia stem cells in vivo with antagomiR–126 nanoparticles in acute myeloid leukemia. Leukemia 2015; 29 (11): 2143–53.47. Lechman ER, Gentner B, van Galen P, et al.Attentiation of miR-126 activity expands HSC in vivo without exhaustion. Cell Stem Cells 2012; 11 (6): 799–811.48. Wang XS, Gong JN, Yu J, et al.MicroRNA-29a and mi-croRNA-142-3p are regulators of myeloid differentiation and acute myeloid keukemia. Blood 2012; 119 (21): 4999–5004.49. Dahhaus M, Rolf C, Ruck C, et al.Expression and prog-nostic significance of hsa-miR-142-3p in acute leukemias. Neo-plasma 2013; 60 (4): 432–38.50. Gong JN, Yu J, Lin HS, et al.The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemia. Cell Death Differ 2014; 21 (1): 100–12.51. Han YC, Park CY, Bhagat G, et al.MicroRNA-29a induc-es aberrant self-renewal capacity in hematopoietic progenitors, bi-ased myeloid development and acute myeloid leukemia. J Exp Med 2010; 207 (3): 475–89.52. Khalay M, Tavankoli M, Stranahan AW, Park CY.Pathogenic microRNA’s in myeloid malignancies. Front Genet 2014; 5: 1–18.53. Wong P, Iwasaki M, Somervaille TC, et al.The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell po-tential by modulating p21 expression. Cancer Res 2010; 70 (9): 3833–42.54. Velu CS, Chaubey A, Phelan JD, et al.Theraupetic antago-nists of microRNAs deplete leukemia-initiating cell activity. J Clin Invest 2014; 124 (1): 222–36.55. Wang Y, Cheng Q, Liu J, Dong M.Leukemia stem cell-re-leased microvesicles promote the survival and migration of myeloid leukemia cells and these effects can be inhibited by microRNA-34a overexpression. Stem Cell Intern 2016; 9: 313–25
